Mark Your 2019 Calendar
New Venue! New Topics! New Speakers!
2018 Attendee Event FAQs
All attendees should have received an email from us detailing the below information.
Q: When and where is next year’s meeting?
A: Next year’s meeting will be held December 9-13, 2019 at the Marriott Marquis San Diego (adjacent to this year's venue).
Q: How can I reserve an exhibit booth at AE&T 2019?
A: To request an AE&T 2019 floor plan with pricing, please contact Kristin Skahan at Kristin.Skahan@knect365.com or +1-857-504-6730.
Q: Does KNect365 host AE&T in Asia or Europe?
A: Yes! KNect365 produces AE&T in both Asia and Europe:
- Antibody Engineering & Therapeutics ASIA - February 26-28, 2019 in Tokyo, Japan
- Antibody Engineering & Therapeutics EUROPE - June 11-13, 2019 in Amsterdam, NL
Q: How many attendees were at AE&T 2018, and where can I see the attendee list?
A: There were slightly more than 900 attendees from 27 countries at this meeting. The attendee list is available in the AE&T conference app, which is valid for 6 months post-event at: https://connect.jujama.com/Antibody-Engineering-Therapeutics. If you need your log in details, please visit the AE&T conference app link above and hit the ‘Retrieve Login Credentials’ link and enter the email associated with your registration to trigger a password reset. If you are still experiencing issues, please contact Event Marketing Manager, Frances Pratt at firstname.lastname@example.org.
Q: How can I access the speaker slides?
A: The speaker slides are saved in the AE&T conference app (use same log in as the mobile app). Once you log in, go to the ‘Presentations’ tab located at the bottom of the left navigation pane. Please note that we are only allowed to post slides from speakers that gave us permission to do so. Many speakers do not give us permission to share their slides due to the legal/proprietary/sensitive nature of the contents. You may contact speakers directly through the AE&T conference app. See previous section for instructions on how to retrieve your log in details.